Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Winton Gibbons, Bill Moffitt, Rollie Carlson, Matt Winkler

Premium

Nanosphere said in recent filings with the US Securities and Exchange Commission that Winton Gibbons will resign from his role as senior vice president of business development at the end of April, and that Bill Moffitt will continue to serve as president and CEO under a new agreement that runs through 2013. The agreement provides Moffitt with a base salary of $458,000 with a possible bonus of up to $275,000. Nanosphere said it has no plans to refill Gibbons' position when he departs.


Asuragen said this week that Rollie Carlson has been appointed president and CEO. Carlson has served as the company's president and chief operating officer. Outgoing CEO Matt Winkler will continue to be chairman of the Austin, Texas-based company, as well as its chief scientific officer.

Carlson has been president of Asuragen since 2006. Prior to joining Asuragen, he held several positions at Abbott Laboratories, including vice president and general manager of the Vysis molecular diagnostic business.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.